Back to top
more

OmniAb, Inc. (OABI)

(Real Time Quote from BATS)

$1.97 USD

1.97
201,033

+0.06 (3.14%)

Updated Aug 4, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 7.69% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -14.29% and 52.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

Zacks Equity Research

Do Options Traders Know Something About OmniAb (OABI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to OmniAb (OABI) stock based on the movements in the options market lately.

Zacks Equity Research

Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.

Zacks Equity Research

Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook

by Zacks Equity Research

Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.